HK Stock Market Move | AINNOVATION(02121) rose more than 4% and reached a strategic cooperation with CloudMigrate Technology to expand the AInnoGC technology platform ecosystem.
Smart innovations (02121) rose more than 4%, as of the time of writing, it rose 4.25% to 4.17 Hong Kong dollars, with a turnover of 399,700 Hong Kong dollars.
AINNOVATION (02121) rose more than 4%, as of the time of writing, it rose 4.25%, to HK$4.17 with a trading volume of HK$399,700.
On the news front, recently, China's leading "AI + manufacturing" solution provider AINNOVATION and the domestically focused enterprise AI application solution provider, Cloudsense Technology, have reached a strategic cooperation. The two parties will not only jointly develop AI application products and solutions in the manufacturing marketing field, explore more typical application scenarios of AI marketing in the manufacturing industry, but also carry out technical platform-level interoperability - AINNOVATION will open its AInnoGC industrial large model technology platform and industrial ontology intelligent body platform interfaces to Cloudsense Technology, expanding the AInnoGC technology platform ecosystem and mutually empowering business development.
Cloudsense Technology is a nationally specialized new small giant enterprise focusing on intelligent solutions for enterprise growth, while AINNOVATION is a nationally specialized new small giant enterprise focusing on "AI + manufacturing," with experience serving more than a thousand large and medium-sized manufacturing enterprises. The industry value of this cooperation lies not only in the resource complementarity of the two "specialized new" enterprises but also in driving industrial AI applications from traditional production quality improvement and efficiency enhancement to downstream marketing value extension in the industrial chain.
Related Articles

QYUNS-B (02509) spent HKD 159,600 to buy back 10,000 shares on June 12th.

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.
QYUNS-B (02509) spent HKD 159,600 to buy back 10,000 shares on June 12th.

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

RECOMMEND





